Found 3 articles
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the second quarter of 2022 and recent business achievements.
GSK and Ionis released promising trial data showing their investigational antisense oligonucleotide, bepirovirsen, could significantly reduce HBsAg and viral DNA levels in patients with CHB.
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Ionis Pharmaceuticals, Inc., announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen, an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus.